Skip to content
Clinical Trials – home
Verifiedinfo

Laiko General Hospital Of Athens

Greece Messogion Avenue 154, 115 27 Athens, Greece

  • 160 trials recruiting
  • Non-small cell lung cancer · Colitis ulcerative · Crohn's disease
  • Adults and children

About Specializations

Laiko General Hospital Of Athens in Athens, Greece specialises in clinical trials of conditions such as Non-small cell lung cancer, Colitis ulcerative, Crohn's disease, Obesity, and other specialisations. This site conducts important research.

Main research areas of the site

Endocrinology and Metabolic Disorders

The medical center is at the forefront of research in Type 2 Diabetes and related metabolic disorders, focusing on innovative treatments that address both obesity and cardiovascular risk. The center's work in this area aims to improve patient outcomes through novel therapeutic approaches.

  • Type 2 Diabetes
  • Obesity and Overweight
  • Cardiovascular Diseases

By integrating cutting-edge research with clinical practice, the center is enhancing the management of chronic conditions associated with metabolic health.

Hematology

Specializing in Hemophilia and other blood disorders, the center is pioneering treatments that significantly reduce bleeding episodes and improve quality of life for patients. The focus is on both prophylactic and gene therapy approaches.

  • Hemophilia
  • Gene Therapy for Hemophilia B

Through advanced research, the center is setting new standards in the treatment of hereditary blood disorders.

Oncology

The center is advancing the field of oncology with a focus on innovative therapies for melanoma and lymphoma. By exploring combination therapies and novel agents, the center aims to improve survival rates and reduce recurrence.

  • Melanoma
  • Diffuse Large B Cell Lymphoma

Research efforts are directed towards developing personalized treatment plans that enhance patient outcomes.

Rheumatology and Autoimmune Diseases

With a strong emphasis on rheumatoid arthritis and systemic lupus erythematosus, the center is exploring new therapeutic options that target the underlying mechanisms of these diseases. The goal is to provide more effective and safer treatment alternatives.

  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Sjögren's Syndrome

Innovative research is leading to breakthroughs in understanding and managing autoimmune conditions.

Nephrology

The center is a leader in the study of IgA Nephropathy and other kidney diseases, focusing on reducing proteinuria and improving renal function. Research in this area is crucial for developing therapies that slow disease progression.

  • IgA Nephropathy
  • Chronic Kidney Disease

By advancing nephrology research, the center is contributing to better management strategies for kidney-related conditions.

Infectious Diseases

Focusing on COVID-19 and other respiratory infections, the center is involved in trials that evaluate the efficacy of immune modulation strategies. This research is vital for improving treatment protocols for hospitalized patients.

  • COVID-19
  • Respiratory Infections

The center's work is instrumental in shaping public health responses to infectious disease outbreaks.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Messogion Avenue 154115 27 AthensGreece
Recruiting now
160 trials
Conditions studied
161
Partner status
Verified

More sites in AthensGreece

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

377 clinical trials

Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:LUNSEKIMIG
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Mrna-4157
  • Sponsor:Merck Sharp & Dohme LLC
Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).